We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Serum α-L-Fucosidase Activity Measured for COVID-19 Infection

By LabMedica International staff writers
Posted on 22 Apr 2021
An unusual fucosylated LacdiNAc in the receptor-binding domains of the spike protein of COVID-19 has been observed. More...
Reduced fucosylation was also found in a specific Fc domain of IgG antibodies in COVID-19 patients that enhanced the interactions with the activating FcγR, FcγRIIIa.

α-L-fucosidase is the enzyme used to catalyze the hydrolytic removal of L-fucose from the fucosylated glycans in the glycoproteins and glycolipids. Removal of fucose from the airway mucus not only impaired the wound closure of the airway, but also regulated the function of immune cells to defense against bacteria and viruses.

Medical Laboratorians at the University of Chinese Medicine (Guangzhou, China) included 585 COVID-19 patients from December 26, 2019, to March 9, 2020, to analyze the correlations of α-L-fucosidase activity with the nucleic acid test, IgM/IgG, comorbidities, and disease progression. An automated hematology analyzer was used to perform blood count (Sysmex Corporation, Kobe, Japan). Analysis of peripheral blood lymphocyte subsets was performed by BD FACSCanto II (Becton, Dickinson, and Company, Franklin Lakes, NJ, USA).

The clinical biochemical analytes were measured on a Roche Cobas 701 (Roche Diagnostics, Rotkreuz, Switzerland). In particular, the serum amyloid (SAA) and C-reactive protein (CRP) measurements were performed based on latex immunoturbidimetry. The serum α-L-fucosidase activity was quantified using MG-2-chloro-4-nitrobenzene-α-L-fucoside (CNPF) as the substrate (Maccura Biotechnology Co., Ltd, Chengdu, China) on a Roche Cobas 701.

The scientists reported that among the COVID-19 patients, 5.75% were double-negative for nucleic acid and antibodies. All of them had increased α-L-fucosidase, while only one had abnormal serum amyloid A (SAA) and C-reactive protein (CRP). The abnormal rate of α-L-fucosidase was 81.82% before the presence of IgM, 100% in the presence of IgM, and 66.2% in the presence of IgG. The team noted that 73.42% of patients with glucometabolic disorders had increased α-L-fucosidase activity and had the highest mortality of 6.33%. The increased α-L-fucosidase was observed in 55.8% of non-severe cases and 72.9% of severe cases, with an odds ratio of 2.12. The α-L-fucosidase mRNA was irrelevant to its serum activity.

The authors concluded that the change in α-L-fucosidase activity in COVID-19 preceded the IgM and SAA and showed a preferable relation with glucometabolic disorders, which may be conducive to virus invasion or invoke an immune response against SARS-CoV-2. The study was published on April 5, 2021 in the journal Clinica Chimica Acta.

Related Links:
University of Chinese Medicine
Sysmex Corporation
Becton, Dickinson, and Company
Roche Diagnostics
Maccura Biotechnology Co




Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Collection and Transport System
PurSafe Plus®
Pipette
Accumax Smart Series
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.